



Ferritin (In-house Binder) Assay Development Report

Theranos, Inc.

February 11, 2012

Prepared by: Karen Shaw

This Assay Development Report contains Theranos Confidential Information and is being provided under the parties' Mutual Confidentiality Agreement. Any further dissemination, use or disclosure of the Report, in whole or in part, is strictly prohibited.



TABLE OF CONTENTS

Theranos Internal Only

[TOC \O "1-3" \H \Z \U] **LIST OF TABLES**

[TOC \h \z \c "Table"]

Theranos Internal Only

LIST OF FIGURES

[TOC \h \z \c "Figure"]

Theranos Internal Only

ASSAY INFORMATION [TC "ASSAY INFORMATION" \f C \l "2"]

1.1 Assay Specifications [TC "Assay Specifications" \f C \l "3"]

The assay is designed to quantitatively detect ferritin in human whole blood, plasma, and serum, with a reportable range of 5-1500 ng/mL. This assay was previously developed using commercial antibodies. This report describes the re-development of the assay using a new in-house biotinylated Fab fragment as the capture.

1.1.1 Reference Assays [TC "Reference Assays and Standards" \f C \l "3"]

The following commercial ELISA kits have been used in-house as predicate methods:

- Alpco Ferritin ELISA Kit (Cat# 25-FERHU-E01)
- GenWay Human Ferritin ELISA Kit (Cat # 40-052-115015)
- IBL Ferritin ELISA Kit (Cat# DB59111)

The originally developed Theranos assay with commercial capture antibody has also been used as the primary reference.

1.1.2 Materials and Methods [TC "Materials and Methods" \f C \l "1"]

A biotin-labeled anti-Ferritin Fab fragment (produced in-house) is coated on an avidin surface and serves as the capture surface. The sample (whole blood, plasma or serum) is diluted and then co-incubated with an alkaline phosphatase-labeled anti-Ferritin antibody on the capture surface for 5 minutes. Then, the surface is washed and the alkaline phosphatase substrate is incubated on the surface for 5 minutes. The resulting chemiluminescence is read in Relative Light Units (RLU).

Table [SEQ Table * ARABIC]: Materials

Reagent Name	Supplier	Catalog #
Ferritin, Native, Liver	Cell Sciences	CSI20324A
Anti-Human Ferritin Biotinylated Fab (C-Ab)	In-house binders group	B1
Mouse Anti-Human Ferritin Antibody (D-Ab)	mybiosource	MBS530750
Alkaline Phosphatase Labeling Kit (SH)	Dojindo	LK13-10
Phospho Glo Substrate	KPL	55-60-04
Blocking Buffer (3% BSA in TBS, 0.05% Sodium Azide)	Sigma (BSA, Fraction V, 99% Pure)	A3059-500G
Carbonate-bicarbonate buffer	Sigma	C3041

ASSAY DEVELOPMENT

[TC "ASSAY OPTIMIZATION" \F C \L "2"]

1.2 Initial Theranos Screen

Dose response of calibrators was tested on the Theranos system for each in-house Fab in comparison to the commercial capture antibody. Aside from changing the capture antibody, all conditions were set using the originally developed assay conditions, including the protocol (Generic2_100X_coincubation_2-1). All in-house Fabs showed some dose response in the assay, with B1 obtaining the most comparable results to the previously developed commercial capture surface.

Table [SEQ Table * ARABIC]: Commercial CAb Dose Response

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	246822	5	801	239719	30	817
1000	161408	23	523	168246	22	574
500	99220	36	322	118764	32	405
250	64917	15	211	64999	18	222
100	23593	11	77	25408	27	87
50	6249	14	20	12192	15	42
25	5888	13	19	7563	27	26
10	2574	5	8	2890	2	10
5	1274	35	4	1491	26	5
0	308	5	1	293	15	1

Table [SEQ Table * ARABIC]: In-House Fab A6 Dose Response

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	65960	25	197	88507	19	257
1000	55916	38	167	51085	25	148
500	21570	23	64	23115	14	67
250	17105	8	51	14987	41	43
100	6788	34	20	7057	7	20
50	3783	11	11	4046	59	12
25	1441	17	4	1490	18	4
10	958	8	3	928	34	3
5	438	6	1	589	11	2
0	335	27	1	345	15	1


Table [SEQ Table * ARABIC]: In-House Fab B1 Dose Response

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	134880	19	386	176745	20	498
1000	126145	14	361	144848	48	408
500	57965	21	166	75120	11	212
250	36889	15	105	41164	8	116
100	13630	38	39	17125	40	48
50	5621	6	16	9072	6	26
25	2319	25	7	4068	21	11
10	1746	17	5	2039	38	6
5	1692	44	5	1159	15	3
0	350	44	1	355	14	1

Table [SEQ Table * ARABIC]: In-House Fab B5 Dose Response

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	130649	21	264	154714	13	308
1000	92000	18	186	88148	27	175
500	55084	1	111	64425	20	128
250	26418	13	53	36034	13	72
100	10459	28	21	11071	16	22
50	5209	32	11	6113	24	12
25	2950	8	6	3714	17	7
10	1409	22	3	1587	10	3
5	782	24	2	1003	30	2
0	495	31	1	503	36	1

Figure [SEQ Figure * ARABIC]: Dose Response Summary



TC "Detection Antibody Conjugate Verification" [C \ "1"]

1.3 Cross Reactivity and Interference

Cross reactivity was tested with α -fetoprotein (AFP), hemoglobin (Hb), transferrin (TRF), and ferric chloride (FeCl₃). Each Fab was tested with a higher than endogenous level of each cross-reactant spiked into assay buffer, as well as a zero control of assay buffer only. All Fabs showed no response to any of the cross-reactants, with spiked values roughly the same as the zero controls.

Next, interference was tested by spiking a high level of each substance into ferritin calibrators. Fab A6 was found to have unacceptable levels of interference. Fab B1 and B5 were selected to continue on for further testing.

Table [SEQ Table * ARABIC]: Cross Reactivity

	AFP (ng/mL)	Mean RLU	CV	Hb (g/dL)	Mean RLU	CV	TRF (mg/dL)	Mean RLU	CV	FeCl ₃ (ug/mL)	Mean RLU	CV
A6	500	378	16	18	263	28	1000	289	18	1000	545	21
	0	357	21	0	357	21	0	357	21	0	357	21
B1	500	327	14	18	232	16	1000	336	23	1000	441	19
	0	313	12	0	313	12	0	313	12	0	313	12
B5	500	322	12	18	276	21	1000	330	23	1000	477	16
	0	396	19	0	396	19	0	396	19	0	396	19

Table [SEQ Table * ARABIC]: Interference (A6)

Ferritin (ng/mL)	Ctrl No Spike		AFP 1500 ng/mL			TRF 3000 ug/mL			FeCl3 1000 ug/mL		
	Mean RLU	CV	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl
1000	50696	34	77421	28	153	39415	48	78	57199	23	113
500	21873	52	39183	33	179	21268	32	97	25002	36	114
100	5276	31	8814	12	167	5396	16	102	7423	22	141
50	3038	18	4984	12	164	4404	15	145	2986	10	98
10	1107	12	2358	14	213	1535	17	139	1102	9	100
0	761	7	1147	15	151	1155	22	152	544	19	71

Table [SEQ Table * ARABIC]: Interference (B1)

Ferritin (ng/mL)	Ctrl No Spike		AFP 1500 ng/mL			TRF 3000 ug/mL			FeCl3 1000 ug/mL		
	Mean RLU	CV	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl
1000	116277	19	133191	20	115	97341	38	84	136018	31	117
500	73484	24	73475	30	100	54955	24	75	56974	21	78
100	13860	29	15651	22	113	13864	34	100	17196	21	124
50	7783	24	9884	23	127	7533	31	97	8172	21	105
10	1509	26	2266	11	150	1985	20	132	2100	25	139
0	320	21	524	15	164	297	50	93	339	23	106

Table [SEQ Table * ARABIC]: Interference (B5)

Ferritin (ng/mL)	Ctrl No Spike		AFP 1500 ng/mL			TRF 3000 ug/mL			FeCl3 1000 ug/mL		
	Mean RLU	CV	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl	Mean RLU	CV	% of Ctrl
1000	74399	21	88289	19	119	105624	20	142	70020	32	94
500	55786	16	63047	16	113	54535	21	98	38239	28	69
100	15094	27	11766	16	78	13279	24	88	10751	30	71
50	6965	6	7543	23	108	6966	12	100	5744	14	82
10	2432	10	2728	7	112	3087	16	127	1108	23	46
0	1391	7	1389	12	100	1263	5	91	370	4	27

1.4 Training Set

Ten clinical samples (previously screened on the reference assays as well as the originally developed Theranos assay) were tested using Fabs B1 and B5. B1 showed significantly better correlation with original assay results. B5 showed under-recovery of all samples and was eliminated from further testing.

Table [SEQ Table * ARABIC]: Training Set (Clinical Correlation)

Sample #	Measured Ferritin, ng/mL					
	B1	B5	Commercial*	Genway*	Alpco*	IBL*
P3	22	12	15	19	20	36
P20	27	16	28	25	24	33
L4	211	114	248	318	336	434
L5	36	16	40	33	36	51
L8	530	271	545	619	597	791
L9	142	70	152	146	145	218
L11	52	32	60	48	52	81
L18	741	366	1002	905	858	807
P5	21	9	18	22	20	25
L16	58	24	55	39	42	70

*Note: results for Theranos assay with commercial capture and results from other reference assays are from previous testing in original assay development. These values were obtained from that report.

Figure [SEQ Figure * ARABIC]: Fab B1 Correlation to Original Assay Results





Figure [SEQ Figure * ARABIC]: Fab B5 Correlation to Original Assay Results



1.5 Effect of Coating Buffers

In-house Fab B1 was coated on tips in four different blocking buffers and compared with control tips coated with commercial capture. StartingBlock provided the best modulation and will be used as the coating buffer for the in-house Fab.

Table [SEQ Table * ARABIC]: Commercial CAB in StartingBlock (Control)

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	218386	10	754	241215	24	688
250	47507	22	164	51055	5	146
25	5108	21	18	5412	17	15
0	290	11	1	351	24	1

Table [SEQ Table * ARABIC]: B1 in 3% BSA Blocking Buffer

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	105644	6	437	142698	3	542
250	21358	31	88	24232	26	92
25	2234	22	9	3369	27	13
0	242	18	1	263	14	1

Table [SEQ Table * ARABIC]: B1 in StartingBlock

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	183278	14	690	170423	18	602
250	22293	25	84	50705	2	179
25	4581	5	17	4038	9	14
0	266	13	1	283	4	1


Table [SEQ Table * ARABIC]: B1 in SeaBlock

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	134341	16	448	158535	31	516
250	28546	3	95	30258	17	99
25	3316	23	11	4289	11	14
0	300	14	1	307	24	1

Table [SEQ Table * ARABIC]: B1 in SuperBlock

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	130147	29	456	105151	14	342
250	22963	35	80	24157	31	79
25	2721	19	10	3010	23	10
0	285	12	1	308	11	1

Figure [SEQ Figure * ARABIC]: Effect of Coating Buffer Summary



1.6 Dilution Linearity

A clinical sample with previously confirmed high ferritin concentration was serially diluted and run in the assay with both commercial and in-house captures. Results with in-house Fab B1 were linear and comparable to commercial results.


Table [SEQ Table * ARABIC]: Dilution Linearity, Commercial CAB

Approx. Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip2 Mean RLU	Tip2 CV
1000	126877	5	119284	46
500	58213	14	66937	25
250	32108	11	35748	20
125	16055	14	20332	4
75	7562	6	8788	8
37.5	5074	20	5494	10

Table [SEQ Table * ARABIC]: Dilution Linearity, In-house Fab B1

Approx. Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip2 Mean RLU	Tip2 CV
1000	92326	21	97007	2
500	51866	21	59503	18
250	21367	38	30696	48
125	13107	16	8910	43
75	5429	21	7093	24
37.5	3650	32	2990	48

Figure [SEQ Figure * ARABIC]: Dilution Linearity Summary



1.7 Capture / Detection Antibody Titration

A series of experiments were performed to determine the optimal concentrations of capture and detection antibodies. First, the coating concentration of the capture antibody (Fab B1) was tested at four levels. (Table 18). Due to higher CVs, the 2.5 µg/mL coating concentration was eliminated.

Next, a small “checkerboard” titration was performed, with three concentrations of B1 and four concentrations of detection antibody tested. (Table 19). The 20 µg/mL concentration was selected for the B1 capture antibody due to the best combination of signal-to-background and CVs.

Finally, the detection antibody was tested again with more calibration points. (Table 20, Figure 6). 1 µg/mL detection antibody provided the best modulation without saturating the top end of the curve. At this stage, assay conditions were fixed at 20 µg/mL CAB, 1 µg/mL DAb.

Table [SEQ Table * ARABIC]: Capture Antibody Titration (DAb fixed at 1 µg/mL)

Ferritin (ng/mL)	B1 20 µg/mL		B1 10 µg/mL		B1 5 µg/mL		B1 2.5 µg/mL	
	Mean RLU	CV	Mean RLU	CV	Mean RLU	CV	Mean RLU	CV
1500	211093	15	140690	17	209704	24	126963	35
250	39152	0	34520	9	40006	19	33232	22
25	4345	22	4791	23	4101	26	2645	41
0	254	15	247	18	233	10	208	20


Table [SEQ Table * ARABIC]: Capture/Detection Checkerboard Titration

DAb (µg/mL)	Ferritin (ng/mL)	B1 20 µg/mL			B1 10 µg/mL			B1 5 µg/mL		
		Mean RLU	CV	S/B	Mean RLU	CV	S/B	Mean RLU	CV	S/B
4	25	14174	18	26	13402	20	12			
	0	544	16		1122	47				
2	25	9181	18	24	9035	30	29	6241	39	17
	0	381	17		314	11		364	20	
1	25	4345	22	17	4791	23	19	4101	26	18
	0	254	15		247	18		233	10	
0.5	25	2712	12	14	2315	21	13	2439	22	12
	0	188	27		174	6		207	17	

Table [SEQ Table * ARABIC]: Detection Antibody Titration (CAB fixed at 20 µg/mL)

Ferritin (ng/mL)	DAb 2 µg/mL		DAb 1 µg/mL		DAb 0.5 µg/mL	
	Mean RLU	CV	Mean RLU	CV	Mean RLU	CV
1500	340675	20	211093	15	107343	17
1000	283382	19	128131	19	85009	51
250	87162	14	39158	0	21945	19
100	35107	11	15268	27	8000	21
25	9181	18	4214	23	2712	12
5	2064	21	1121	19	654	24

Figure [SEQ Figure * ARABIC]: Final Detection Antibody Titration Summary



1.8 Assay Formats Comparison

The assay was tested using a stepwise protocol instead of the originally developed co-incubation format. Both with and without post-sample wash, the stepwise protocol drastically reduced modulation, without providing any improvement in CVs. Thus, the co-incubation format was confirmed to be the optimal choice for this assay.

Table [SEQ Table * ARABIC]: 10-10-10 Stepwise

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	97101	14	82	80782	12	79
1000	50588	25	42	55027	44	54
250	17848	14	15	13956	21	14
100	6546	2	5	6685	3	7
5	1508	2	1	1412	33	1
0	1190	11	1	1022	11	1

Table [SEQ Table * ARABIC]: 10-10-10 Stepwise with PSW

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	76435	26	77	79356	12	67
1000	42323	17	42	43723	16	37
250	12011	19	12	12797	41	11
100	6425	22	6	5722	11	5
5	1384	23	1	1580	21	1
0	996	26	1	1188	1	1

1.9 Effect of protocol (Sample dilution and incubation times)

The effect of adjusting the assay protocol was evaluated. First, incubation time was kept the same (2-1 minute), but sample dilutions of 150X and 200X were tested. (Table 23 and 24, Figure 7). There was no advantage found for diluting beyond the original 100X.

Next, incubation times of 5-5 minutes and 10-10 minutes were tested in place of the 2-1 minute original protocol. (Table 25 and 26, Figure 8). Due to the additional incubation time, detection antibody for these protocols was adjusted down 10-fold, to 100 ng/mL. The 5-5 minute incubation time showed an improvement in CVs without saturating at the top end of the curve. This condition was re-tested and the result was confirmed. (Table 27). In addition, the longer incubation time resulted in reducing the RLU difference between replicate 1 and replicate 2, eliminating the need to calibrate each replicate separately. The protocol was set as Generic2_100X_coincubation_5-5.

Table [SEQ Table * ARABIC]: 150X Sample Dilution

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	123735	27	461	147269	16	543
1000	91869	23	342	113213	2	418
250	23953	20	89	24628	14	91
100	10325	12	38	12812	26	47
5	929	15	3	1006	24	4
0	269	23	1	271	26	1

Table [SEQ Table * ARABIC]: 200X Sample Dilution

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	76027	27	249	71337	14	214
1000	66021	26	216	85276	10	256
250	19342	27	63	22398	20	67
100	9227	13	30	7889	30	24
5	590	20	2	776	18	2
0	305	35	1	333	30	1

Figure [SEQ Figure * ARABIC]: Sample Dilution Summary




Table [SEQ Table * ARABIC]: 10-10 Co-Incubation

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	274950	15	1183	309416	10	1291
1000	217109	19	934	221902	22	926
100	30294	17	130	27843	25	116
5	1929	17	8	1868	14	8
0	232	28	1	240	8	1

Table [SEQ Table * ARABIC]: 5-5 Co-Incubation

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	130827	16	693	144867	5	747
1000	86682	n/a	459	91660	28	472
100	10887	11	58	12253	6	63
5	811	5	4	821	22	4
0	189	16	1	194	19	1

Figure [SEQ Figure * ARABIC]: Incubation Times Summary




Table [SEQ Table * ARABIC]: 5-5 Co-Incubation Confirmation

Ferritin (ng/mL)	Tip1 Mean RLU	Tip1 CV	Tip1 Modulation	Tip2 Mean RLU	Tip2 CV	Tip2 Modulation
1500	112080	10	630	113289	3	759
1000	79745	26	448	83118	20	557
100	10109	18	57	9659	n/a	65
25	2701	2	15	2831	17	19
5	782	10	4	821	3	6
0	178	13	1	149	8	1


1.10 Determination of Expected LLOQ and ULOQ

The full 10-point calibration curve was run under finalized assay conditions to establish the LLOQ/ULOQ. Target was to meet or exceed originally developed assay LLOQ/ULOQ of 10 ng/mL and 1000 ng/mL, respectively. The finalized assay with the B1 Fab resulted in a curve with LLOQ of 5 ng/mL and ULOQ of 1500 ng/mL.

Table [SEQ Table * ARABIC]: Final 10-point Calibration Curve

Ferritin (ng/mL)	Mean RLU	CV	Modulation
1500	112564	7	688
1000	81094	21	495
500	43324	13	265
250	24818	15	152
100	10736	13	66
50	5878	5	36
25	2766	11	17
10	994	17	6
5	802	7	5
0	164	14	1

Figure [SEQ Figure * ARABIC]: Calibration Curve (LLOQ/ULOQ)



1.11 Final Clinical Correlation


Ten previously tested clinical samples were run in the finalized assay and compared to prior results. Correlation with original assay was found to be acceptable.

Table [SEQ Table * ARABIC]: Clinical Correlation, Final Conditions

Sample #	Measured Ferritin, ng/mL				
	B1 Finalized	Commercial*	Genway*	Alpco*	IBL*
P20	24	28	25	24	33
L4	213	248	318	336	434
L5	30	58	46	51	65
L7	60	58	46	51	65
L8	409	545	619	597	791
L9	135	152	146	145	218
L11	43	60	48	52	81
L14	109	122	129	134	216
L16	47	55	39	42	70
L18	829	1002	905	858	807

*Note: results for Therasnos assay with commercial capture and results from other reference assays are from previous testing in original assay development. These values were obtained from that report.

Figure [SEQ Figure * ARABIC]: Finalized Fab B1 Correlation to Original Assay Results



1.12 Reproducibility

Three separate lots of in-house Fab B1 were produced and coated on tips. A full calibration curve and 4 clinical samples were run in the assay on each lot of coated tips. Results were very comparable across all three lots, indicating that the production process is reproducible.

Table [SEQ Table * ARABIC]: Reproducibility, Calibration Curves

ferritin (ng/mL)	Lot 1		Lot 2		Lot 3	
	Mean RLU	CV	Mean RLU	CV	Mean RLU	CV
1500	137732	16	138710	10	142551	18
500	44742	19	52103	21	57686	21
250	27336	16	23827	25	31793	10
100	9572	11	12422	12	14143	19
25	2621	38	3253	10	3153	9
10	1227	4	1082	23	1236	21
5	699	12	576	24	659	12
0	100	35	150	17	113	19

Table [SEQ Table * ARABIC]: Reproducibility, Clinical Samples

Sample #	Measured Ferritin, ng/mL				
	Lot 1	Lot 2	Lot 3	Mean	Lot-to-lot CV
L4	208	173	171	184	11.3
L8	564	460	389	471	18.6
L14	121	89	75	95	24.8
L16	51	45	45	47	7.1

1.13 Stability Studies

Stability of reagents was tested to 12 weeks. For the final two time-points, fresh capture tips and detection antibody solutions were prepared and tested in parallel with stability capture and detection reagents. Performance of stability reagents matched performance of fresh reagents, indicating that reagents are stable up to 12 weeks at 4°C. In-house Fab B1 may now be used as capture in the Theranos ferritin assay under these finalized conditions.

Table [SEQ Table * ARABIC]: Stability

Ferritin ng/mL	Mean RLU									
	Day 1	Day 4	Day 7	Day 11	Week 3	Week 4	Week 8 Stab.	Week 8 Fresh	Week 12 Stab.	Week 12 Fresh
500	50638	45317	41517	33717	46026	31001	33720	31791	35177	34049
50	6218	5433	5587	4690	4507	4540	4347	4112	3361	4941
10	1406	1204	1077	1081	906	841	1023	640	955	998
0	115	110	84	96	105	79	62	79	81	104

Figure [SEQ Figure * ARABIC]: Stability

